KRAS and breast cancer: Given that MDA MB 231 breast cancer cells express activated G13D KRas and moderately activated G464V BRaf (Davies et al., 2002), while MDA MB 435 melanoma cells express oncogenic V600E BRaf, increased KRas signal output was not the result of selection for cells with de novo Ras/MAPK pathway mutations.